Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Minervax

Minervax logo

 

Almost half of all serious bacterial infections in newborn babies are caused by group B streptococcus (GBS). These bacteria are carried by around one in four women. Professor Gunnar Lindahl and Dr Thomas Areschoug have now developed a possible vaccine against the infection. The vaccine became basis of the pharmaceutical company Minervax. The company is now based in Denmark.

Minervax website

 

 

Minervax

Develop a novel vaccine candidate against Group B Streptococci (GBS)

 

Founded by Professor Gunnar Lindahl with research team.

Portfolio company since 2010.

 

Portfolio Manager LU Holding:

christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78